CYP2J6 CRISPR Activation Plasmid (m): sc-419921-ACT
- Target species: mouse
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- CYP2J6 CRISPR Activation Plasmid (m) is a synergistic activation mediator (SAM) transcription activation system designed to specifically upregulate gene expression
- CYP2J6 CRISPR Activation Plasmid (m) consists of three plasmids at a 1:1:1 mass ratio: a plasmid encoding the deactivated Cas9 (dCas9) nuclease (D10A and N863A) fused to the transactivation domain VP64, and a blasticidin resistance gene; a plasmid encoding the MS2-p65-HSF1 fusion protein, and a hygromycin resistance gene; a plasmid encoding a target-specific 20 nt guide RNA fused to two MS2 RNA aptamers, and a puromycin resistance gene
- The resulting SAM complex binds to a site-specific region approximately 200-250 nt upstream of the transcriptional start site and provides robust recruitment of transcription factors for highly efficient gene activation
- gRNAs encoded by CYP2J6 CRISPR Activation Plasmid (m) and CYP2J6 CRISPR Activation Plasmid (m2) target distinct regulatory regions upstream of the Cyp2j6 transcriptional start site. One or both designs may be available
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
CYP2J6 CRISPR Activation Plasmid (m) | sc-419921-ACT | 20 µg | $397.00 |
Mouse Cyp2j6 encodes CYP2J6, a cytochrome P450 monooxygenase that catalyzes oxidative metabolism of endogenous lipids and xenobiotics, including the formation of bioactive epoxy fatty acids from polyunsaturated fatty acids. Through modulation of arachidonic acid and related eicosanoid networks, CYP2J6 can influence redox balance, inflammatory signaling, and vascular tone–associated processes. Variation in Cyp2j6 expression is relevant to studies of hepatic and extrahepatic drug metabolism, chemical toxicity, and lipid mediator biology in mouse models. Its activity intersects with pathways that shape oxidative stress responses and inflammatory homeostasis, providing mechanistic context for cardiometabolic and immunometabolic phenotypes in preclinical research.
CYP2J6 CRISPR Activation Plasmid (m) provides a targeted, non-destructive approach to upregulating endogenous Cyp2j6 expression without altering the underlying DNA sequence.
CYP2J6 CRISPR Activation Plasmid (m) is a three-plasmid synergistic activation mediator (SAM) system engineered for highly efficient, site-specific transcriptional upregulation of the Cyp2j6 locus in human cell lines. The system is built around a catalytically inactive Cas9 (dCas9) carrying two inactivating mutations (D10A and N863A) that eliminate nuclease activity while preserving DNA binding. This dCas9 is fused to VP64, a potent transcriptional activator, and is co-expressed with a blasticidin resistance gene for selection. The second plasmid encodes the MS2-p65-HSF1 fusion protein, a secondary activator complex that works in concert with dCas9-VP64, alongside a hygromycin resistance gene. The third plasmid encodes a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers that recruit the MS2-p65-HSF1 complex to the activation site, accompanied by a puromycin resistance gene. The three plasmids are delivered at a 1:1:1 mass ratio for balanced expression of all system components.
Once assembled at the target locus, the SAM complex binds within approximately 200 bp upstream of the Cyp2j6 transcriptional start site, where VP64, p65, and HSF1 act in concert to recruit transcriptional machinery and drive upregulation of endogenous CYP2J6 expression. Unlike nuclease-active Cas9, dCas9 does not introduce double-strand breaks or modify the genomic sequence, preserving the native Cyp2j6 locus and enabling the study of CYP2J6-dependent transcriptional responses at the endogenous locus, making it a valuable tool for functional studies, target gene identification, and the modeling of CYP2J6 pathway restoration in tumor cells with silenced or reduced Cyp2j6 expression.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.